report banner

News in English

PostPress Release

Options Exercised II

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.
Learn more …
PostPress Release

Options Exercised I

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.
Learn more …
PostNews: Press Release

Novel HoloMonitor based research to be presented at cancer research annual meeting

Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the novel research results.
Learn more …
PostNews: Press Release

Japan´s foremost medical institute purchases multiple HoloMonitor instruments

Japan’s foremost medical research institute, The Institute of Medical Science at University of Tokyo, recently purchased two HoloMonitor M4. Together with RIKEN and Kyoto University, the institute spearheads Japan’s national effort to become the undisputed leader of regenerative medicine in the world.
Learn more …
PostNews: Press Release

EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research

The European Commission has appointed Phase Holographic Imaging,Bundesanstalt für Material-forschung und Prüfung (Germany’s federal technology research institute), Malmö, Umeå, Copenhagen and Turku University to develop improved methods for clinically diagnosing cancer.
Learn more …
PostNews: Press Release

American association of cancer research highlights article published by PHI collaborators

In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nanomedicine against ovarian cancer developed by scientists from the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University.
Learn more …
1222324252632